These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 1277724)

  • 1. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK; De Schepper PJ
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired plasma phenytoin binding in uremia. Effect of in vitro acidification and anion-exchange resin.
    Depner TA; Stanfel LA; Jarrard EA; Gulyassy PF
    Nephron; 1980; 25(5):231-7. PubMed ID: 7383235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin.
    Shoeman DW; Benjamin DM; Azarnoff DL
    Ann N Y Acad Sci; 1973 Nov; 226():127-30. PubMed ID: 4520391
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
    Odar-Cederlof I
    Clin Pharmacokinet; 1977; 2(2):147-53. PubMed ID: 324689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A; Havlik D
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenytoin-oxacillin interactions in normal and uremic sera.
    Dasgupta A; Sperelakis A; Mason A; Dean R
    Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.
    Ehrnebo M; Odar-Cederlöf I
    Eur J Clin Pharmacol; 1975 Aug; 8(6):445-53. PubMed ID: 1233247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein binding, plasma concentrations, and effects of diphenylhydantoin in man.
    Lund L; Lunde PK; Rane A; Borga O; Sjöqvist F
    Ann N Y Acad Sci; 1971 Jul; 179():723-8. PubMed ID: 4998913
    [No Abstract]   [Full Text] [Related]  

  • 17. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia.
    Allison TB; Comstock TJ
    Ther Drug Monit; 1988; 10(4):376-81. PubMed ID: 3201522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age and sex on the plasma binding of acidic and basic drugs.
    Verbeeck RK; Cardinal JA; Wallace SM
    Eur J Clin Pharmacol; 1984; 27(1):91-7. PubMed ID: 6489431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of total drug concentration on the free fraction in uremic sera.
    Tiula E; Neuvonen PJ
    Ther Drug Monit; 1986; 8(1):27-31. PubMed ID: 3961893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.